CSF2 and COVID-19: Two small pilot studies have indicated that targeting GM-CSF in patients with severe COVID-19 lung diseases using anti–GM-CSF receptor monoclonal antibodies mavrilimumab or lenzilumab, respectively, may be a strategy for improving clinical outcomes (3, 4), although larger controlled clinical trials would be needed to determine efficacy and biological impact of such approaches.